Edition:
United States

Altimmune Inc (ALT.OQ)

ALT.OQ on NASDAQ Stock Exchange Global Market

0.34USD
4:00pm EDT
Change (% chg)

$-0.00 (-0.56%)
Prev Close
$0.34
Open
$0.34
Day's High
$0.35
Day's Low
$0.33
Volume
42,562
Avg. Vol
117,956
52-wk High
$3.16
52-wk Low
$0.25

Latest Key Developments (Source: Significant Developments)

Altimmune Announces Financial Results For Year Ended Dec 31
Wednesday, 28 Mar 2018 04:44pm EDT 

March 28 (Reuters) - Altimmune Inc ::ALTIMMUNE ANNOUNCES FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2017 AND PROVIDES CORPORATE UPDATE.ALTIMMUNE - AT DECEMBER 31, 2017, HAD CASH, CASH EQUIVALENTS, AND RESTRICTED CASH OF APPROXIMATELY $12.3 MILLION.  Full Article

Hudson Bay Capital Management Reports A 9.99 Percent Passive Stake In Altimmune
Friday, 2 Feb 2018 01:25pm EST 

Feb 2 (Reuters) - Hudson Bay Capital Management LP ::HUDSON BAY CAPITAL MANAGEMENT LP‍ REPORTS A 9.99 PERCENT PASSIVE STAKE IN ALTIMMUNE, INC​ AS OF DECEMBER 31, 2017 - SEC FILING.  Full Article

Altimmune Elects Mitchel Sayare As Chairman Of Its Board
Wednesday, 3 Jan 2018 08:00am EST 

Jan 3 (Reuters) - Altimmune Inc ::ALTIMMUNE ELECTS MITCHEL SAYARE, PH.D. AS CHAIRMAN OF ITS BOARD OF DIRECTORS.ALTIMMUNE INC - BOARD'S CURRENT CHAIRMAN, DAVID DRUTZ WILL REMAIN ON AS CHAIRMAN OF COMPENSATION COMMITTEE AND MEMBER OF BOARD.  Full Article

Altimmune reports Q3 loss per share $2.05
Thursday, 9 Nov 2017 04:01pm EST 

Nov 9 (Reuters) - Altimmune Inc :Altimmune announces third quarter 2017 financial results and provides corporate update.Q3 loss per share $2.05.Q3 preliminary loss per share $0.34 excluding items.Altimmune Inc qtrly revenue and grants and contracts were $4.6 million versus $0.9 million​.Altimmune Inc - ‍at september 30, 2017, company had cash and cash equivalents of approximately $17.1 million​.Altimmune Inc - ‍initiated a phase 2 clinical trial with nasovax vaccine with initial data expected in q1 2018​.  Full Article

Altimmune submits investigational new drug application for Nasovax for phase 2 trial preparation
Monday, 21 Aug 2017 08:00am EDT 

Aug 21 (Reuters) - Altimmune Inc :Altimmune submits investigational new drug application for Nasovax in preparation for Phase 2 trial.Previous versions of Nasovax evaluated in two phase 1 studies under earlier inds were immunogenic and well tolerated.Phase 2 data is expected sometime in Q1 of 2018.  Full Article

Altimmune announces $14.7 million Series B preferred stock offering
Thursday, 17 Aug 2017 08:00am EDT 

Aug 17 (Reuters) - Altimmune Inc :Altimmune announces $14.7 million Series B preferred stock offering.Altimmune - To use net proceeds from this financing for continued advancement of development activities for company's clinical-stage product pipeline​.  Full Article

Altimmune posts Q2 loss of $0.26 per share
Thursday, 10 Aug 2017 12:24am EDT 

Aug 10 (Reuters) - Altimmune Inc :Altimmune announces second quarter 2017 financial results and provides corporate update.Remains on track to initiate Phase 2 trial in Nasovax in Q3.Altimmune Inc - expect to have sufficient resources to fund our current and planned development programs through key clinical milestones and 2Q 2018.Qtrly net loss per share $0.26.Altimmune - Quaterly revenue and grants and contracts were $3.0 million and $3.3 million, respectively, compared to $0.8 million and $1.3 million.  Full Article

Healthcap V L.P. reports a 7.5 percent passive stake in Altimmune Inc
Monday, 15 May 2017 05:31pm EDT 

May 15 (Reuters) - Altimmune Inc :Healthcap V L.P. Reports a 7.5 percent passive stake in Altimmune Inc as of May 4, 2017 - SEC filing.  Full Article

Philip Hodges reports a 8.54 percent stake in Altimmune Inc
Monday, 15 May 2017 05:22pm EDT 

May 15 (Reuters) - Altimmune Inc :Philip Hodges reports a 8.54 percent stake in Altimmune Inc as of May 4, 2017 - SEC filing.  Full Article

Truffle Capital reports 10.1 pct passive stake in Altimmune
Monday, 15 May 2017 05:08pm EDT 

May 15 (Reuters) - Truffle Capital S.A.S.::Truffle Capital S.A.S. reports 10.1 percent passive stake in Altimmune Inc as on May 4, 2017 - SEC filing.  Full Article

BRIEF-Altimmune Q1 Loss Per Share $0.25

* ALTIMMUNE ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE